首页> 美国卫生研究院文献>Molecules >Synthesis Characterization X-ray Crystallography Acetyl Cholinesterase Inhibition and Antioxidant Activities of Some Novel Ketone Derivatives of Gallic Hydrazide-Derived Schiff Bases
【2h】

Synthesis Characterization X-ray Crystallography Acetyl Cholinesterase Inhibition and Antioxidant Activities of Some Novel Ketone Derivatives of Gallic Hydrazide-Derived Schiff Bases

机译:没食子酰肼衍生希夫碱的一些新型酮衍生物的合成表征X射线晶体学乙酰胆碱酯酶抑制和抗氧化活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer’s disease (AD) is the most common form of dementia among older people and the pathogenesis of this disease is associated with oxidative stress. Acetylcholinesterase inhibitors with antioxidant activities are considered potential treatments for AD. Some novel ketone derivatives of gallic hydrazide-derived Schiff bases were synthesized and examined for their antioxidant activities and in vitro and in silico acetyl cholinesterase inhibition. The compounds were characterized using spectroscopy and X-ray crystallography. The ferric reducing antioxidant power (FRAP) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays revealed that all the compounds have strong antioxidant activities. N-(1-(5-bromo-2-hydroxyphenyl)-ethylidene)-3,4,5-trihydroxybenzohydrazide (>2) was the most potent inhibitor of human acetyl cholinesterase, giving an inhibition rate of 77% at 100 μM. Molecular docking simulation of the ligand-enzyme complex suggested that the ligand may be positioned in the enzyme’s active-site gorge, interacting with residues in the peripheral anionic subsite (PAS) and acyl binding pocket (ABP). The current work warrants further preclinical studies to assess the potential for these novel compounds for the treatment of AD.
机译:阿尔茨海默氏病(AD)是老年人中最常见的痴呆形式,该病的发病机制与氧化应激有关。具有抗氧化活性的乙酰胆碱酯酶抑制剂被认为是AD的潜在治疗方法。合成了一些新的没食子酰肼衍生的席夫碱的酮衍生物,并检查了它们的抗氧化活性以及体外和计算机上的乙酰胆碱酯酶抑制作用。使用光谱学和X射线晶体学对化合物进行表征。还原铁的抗氧化能力(FRAP)和2,2-二苯基-1-吡啶并肼基(DPPH)测定表明,所有化合物均具有很强的抗氧化活性。 N-(1-(5-溴-2-羟基苯基)-亚乙基)-3,4,5-三羟基苯甲酰肼(> 2 )是最有效的人乙酰胆碱酯酶抑制剂,抑制率达100μM时为77%。配体-酶复合物的分子对接模拟表明,配体可能位于酶的活性位点峡谷中,与周围的阴离子亚位点(PAS)和酰基结合袋(ABP)中的残基相互作用。目前的工作需要进行进一步的临床前研究,以评估这些新型化合物治疗AD的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号